Articles tagged with Alzheimer Disease
A new gene therapy approach has shown promising results in slowing the progression of Alzheimer's disease by reducing cognitive decline. The therapy, which involves delivering nerve growth factor to the brain, demonstrated significant improvements in patients' mental status and brain activity.
A study found that short heparansulfate chains trigger amyloid deposits, which are associated with Alzheimer's disease. The research suggests that short segments of sugar chains may be useful in developing new drugs for the condition.
A team of researchers from Case Western Reserve University propose an alternate view on the pathology of Alzheimer's disease (AD), suggesting that neurofibrillary tangles (NFTs) may be protective against oxidative stress. NFT-bearing neurons can survive for decades, and their presence may be a response to reduce oxidative damage.
A study published by Johns Hopkins Medicine suggests that participating in a variety of physical activities may reduce the risk of Alzheimer's disease in older adults. The research found that individuals who engaged in multiple activities had a lower risk of dementia compared to those who participated in fewer activities.
A study of 68 patients with probable Alzheimer's disease found that higher levels of spirituality and religiosity may slow cognitive decline. Spirituality and private religious practices accounted for 20% of the total variance in cognitive decline.
A major clinical trial suggests that the use of donepezil may delay the clinical diagnosis of Alzheimer's disease in people with mild cognitive impairment, with a 58% reduced risk at one year. The study also highlights the importance of considering genetic factors, such as apolipoprotein E-4, in making treatment decisions.
A Mayo Clinic study showed that donepezil treatment may slow the progression from mild cognitive impairment to Alzheimer's disease. Patients with a specific genotype had a longer response to the treatment, which could lead to new horizons in early treatment and prevention.
The American Academy of Neurology presented Leeza Gibbons with the Public Leadership in Neurology Award for her advocacy work on Alzheimer's disease. Her foundation, Leeza's Place, provides community-based locations offering comfort, education, and care to those affected by memory disorders.
Dr. Morris and Dr. Petersen have developed methods to detect preclinical Alzheimer's disease, a precursor to the onset of symptoms. Their research has the potential to identify a pre-clinical stage of AD that can be targeted for disease-modifying therapies.
Researchers found that a diet rich in docosahexenoic acid (DHA) significantly slowed Alzheimer's disease progression in mice by reducing harmful brain plaques. This study suggests that boosting DHA intake may delay or prevent the disease, even for those genetically predisposed.
Researchers have developed a polymer that acts as a decoy for beta amyloid proteins, attracting them away from brain cells and preventing their accumulation. This approach shows promise for slowing Alzheimer's disease progression and may lead to the development of new diagnostic tools.
Research found that enriched mice had lower levels of b-amyloid peptides, which form toxic brain tangles in Alzheimer's disease. The enrichment act as a protective factor, keeping peptide levels low before they can aggregate and cause problems.
Mice raised in an enriched environment with running wheels and toys showed reduced beta-amyloid deposits and increased enzyme activity. They also exhibited improved genes involved in learning, memory, brain cell survival, and blood vessel growth.
A study of 180 Catholic nuns and priests found that nearly half with mild cognitive impairment met pathologic criteria for Alzheimer's disease. Meanwhile, about a quarter had cerebral infarcts, indicating a possible 'reserve' capacity in the brain that prevents cognitive decline despite pathology.
Insulin production in the brain contributes to Alzheimer's progression, with growth factors playing a key role. Researchers found reduced insulin levels in affected areas, opening door for targeted brain treatment.
A study found that Seroquel significantly reduced symptoms of agitation in elderly patients with Alzheimer's disease, improving their quality of life. The treatment was well-tolerated, with no decline in cognitive function observed.
A UCI research team identified beta amyloid accumulation within neurons as the trigger for Alzheimer's memory decline in mice. By clearing away excess beta amyloid, they were able to correct memory impairments. The findings have implications for developing drugs targeting beta amyloid.
Researchers at MGH have identified a potential Alzheimer's risk gene variant that moderately raises the risk of developing the disease. The study found that specific changes in the ubiquilin-1 gene sequence occurred more frequently in individuals with Alzheimer's than in their unaffected siblings.
Scientists observed a breakdown in neuronal transport, leading to abnormal protein buildup and neuron failure. The study suggests that impaired axonal transport may be an early indicator of Alzheimer's disease.
Researchers developed a conformation-dependent immunoassay (CDI) that detects prions in human brain tissue, outperforming standard immunological methods. CDI detected abnormal prions in all sampled brain regions, suggesting its potential for accurate diagnosis of prion diseases like CJD.
The UT Southwestern Medical Center has begun using telemedicine for periodic checkups with Choctaw Nation patients in Oklahoma. This allows doctors to assess disease progression and medication side effects remotely, reducing travel time and increasing convenience.
Researchers at University of California - Irvine find that chronic nicotine exposure increases neurofibrillary tangles in a mouse model of Alzheimer's disease, contradicting previous studies. The study highlights the importance of investigating therapies for both plaque and tangle formations in Alzheimer's.
Scientists have discovered that gamma-secretase, a key enzyme involved in Alzheimer's disease, has diverse tissue-specific activity. This finding opens up new possibilities for developing targeted treatments by focusing on the inactivation of specific sub-units, which may reduce side effects.
A new nanoscale diagnostic technique has been developed to detect possible traces of Alzheimer's disease in cerebrospinal fluid. The procedure uses magnetic and DNA particles to identify biomarkers, which could lead to early diagnosis and effective treatment if proven successful.
Scientists at Northwestern University have developed a new diagnostic test for Alzheimer's disease using bio-bar-code amplification technology. The test can detect miniscule amounts of a toxic protein in human cerebrospinal fluid, which may be responsible for early neurological deterioration.
A study found that healthy older adults with the e-4 allele of the ApoE gene exhibit significantly worse prospective memories, struggling to remember tasks even when instructed to do so. The findings suggest a strong impact of genetic variation on cognitive function and recommend reevaluating the role of ApoE in cognition.
Researchers found that clearing Alzheimer's plaques leads to rapid recovery of normal brain structure in just three days. The study suggests that plaque-clearing treatments may slow or halt disease progression, and researchers plan to investigate the underlying mechanisms.
Researchers have discovered that reducing Abeta buildup in the brain can rapidly reverse structural nerve damage associated with Alzheimer's disease. The study used a mouse model to demonstrate the effectiveness of an anti-Abeta antibody treatment, suggesting a potential new approach for treating the condition.
Researchers have identified integrin [alpha]v[beta]6 as a key risk factor for developing early-stage colorectal cancer. The molecule's high levels are also predictive of patient survival, with low expression associated with better outcomes.
Researchers have identified a potential therapeutic application for the new drug Nifrolidine in treating nicotine addiction and Alzheimer's disease. The study found that Nifrolidine binds to specific brain receptors implicated in these conditions, offering hope for early diagnosis and treatment.
A study by Mount Sinai School of Medicine found that mice fed a reduced carbohydrate diet slowed disease progression, with anti-amyloidogenic activities increased and plaque development prevented. The findings provide a possible mechanism for caloric reduction to prevent Alzheimer's disease.
Researchers found that weight loss was significantly associated with incident dementia, regardless of confounding factors. The study suggests that monitoring weight change and nutritional state in people with dementia is crucial for prevention and minimization.
Research suggests that statins can increase 'healthy' (non-amyloidogenic) cleavage of amyloid precursor protein (APP), potentially protecting against Alzheimer's disease. In a study, two different statins increased healthy cleavage of APP in mouse neuroblastoma cells.
Researchers found that statins may break down toxic amyloid-beta by inhibiting the Rho/ROCK pathway, which could lead to new anti-amyloid drug targets. The study suggests that statins may be a promising strategy in treating Alzheimer's disease.
A UCLA-VA study found that curcumin inhibits beta amyloid formation and breaks up existing brain plaques in genetically altered mice. Curcumin's low molecular weight and polar structure allow it to penetrate the blood-brain barrier effectively, making it a promising treatment option for Alzheimer's disease.
Research reviews medical studies on mixed dementia and finds that treating cardiovascular risk factors like high blood pressure can be more effective in protecting brain function. This approach shows promise as a complementary strategy to memory-preserving drugs.
Researchers found that a diet-restricted group of mice showed a 50% reduction in beta-amyloid plaques, a substance linked to memory loss and Alzheimer's disease. The study, conducted with collaborators at the University of South Florida, used mice with human genes altered for early onset hereditary Alzheimer's.
UT Southwestern researchers developed a gene-based vaccine to stimulate immune systems against amyloid protein, reducing plaque buildup and cognitive loss in mice. The study aims to create a safe and effective Alzheimer's vaccine that can prevent or slow disease progression.
A recent study identified lemons and lilac as among the top 10 smells that can predict Alzheimer's Disease. The study analyzed smell identification test results from patients with Alzheimer's disease and healthy elderly subjects, revealing a strong link between the inability to identify specific odors and the development of the disease.
Researchers identified a shortfall of IDE protein in Alzheimer's patients and found a cause-effect relationship between insulin signaling and increased production of IDE. A low-fat diet high in fish and soy was shown to increase production of IDE, suggesting a potential protective effect against Alzheimer's disease.
Research found that toxic amyloid ß-derived diffusible ligands (ADDLs) specifically attack and disrupt synapses in the brain, leading to memory loss in Alzheimer's patients. Understanding how ADDLs target specific neurons and synapses could lead to new therapeutic drugs capable of reversing memory loss.
Researchers found that brief treatment with rolipram improved memory and cognitive function in both young and older mice, suggesting potential therapeutic benefits. The study also showed that the effects of treatment lasted for at least two months after treatment ended.
Researchers analyzed three of Iris Murdoch's works, including her final novel, to study the effects of Alzheimer's on language. The findings suggest a decline in vocabulary and simplified language in her final novel, consistent with early stages of the disease.
Researchers used computer simulations to visualize the formation of amyloid fibrils, similar to those found in Alzheimer's and Parkinson's patients. The study suggests that understanding how these fibrils form could lead to discoveries of how to slow or halt their growth.
Researchers detected distinct brain activation patterns in individuals carrying the APOE-å4 risk factor and found potential evidence of early Alzheimer's changes. The study suggests that these individuals may be compensating for damage by switching to alternate brain networks, providing insights into disease predisposition.
A study suggests that consuming antioxidant-rich foods, particularly apples, may reduce the risk of developing Alzheimer's disease. Quercetin, found in apples' skin, has shown stronger protective effects against neurotoxicity compared to vitamin C.
Researchers aim to block harmful immune response in brain inflammation and remove beta amyloid plaques with anti-CD40 ligand antibody and investigational vaccine. The study builds on previous USF laboratory studies tracking the role of microglia in Alzheimer's disease.
A new study shows that a cholesterol-lowering medication can improve symptoms of depression and cognition in people with mild-to-moderate Alzheimer's disease. The treatment, atorvastatin, reduced bad cholesterol by more than 50% and showed significant improvement in depression symptoms.
Researchers discovered a new class of compounds, aminopyridazines, that target neuroinflammation and neuronal loss in Alzheimer's disease. The compounds inhibit glial activation and reduce oxidative stress, leading to decreased neuron loss and improved cognitive function.
A new genetic study identified strong evidence for Alzheimer's genes on chromosomes 18 and 10, expanding our knowledge of the disease. The research, conducted on Hispanic families in the Dominican Republic, sheds light on the complex interaction of multiple genes that contribute to Alzheimer's.
A UK researcher has made significant breakthroughs in understanding the mechanisms of Alzheimer's disease. The study found that methionine in the human amyloid beta peptide is a key contributor to the disease, causing damage to neurons and decreased cell viability.
Apolipoprotein E is responsible for converting harmless amyloid-beta protein into toxic filamentous amyloid, a major hallmark of Alzheimer's disease. Mice with the gene showed memory deficits only when it was present.
A team is using technology to monitor and analyze patients' daily activities, providing a more accurate picture of their condition. The study compares traditional methods with high-tech devices, aiming to develop better ways to support those with dementia.
A study using antibody microarrays measured levels of over 500 proteins in tissue samples from patients with epilepsy and Alzheimer's disease, identifying increased signal transduction proteins as a possible new target for treatment. This discovery could lead to the development of new medications for these conditions.
A team of researchers from the University of Arizona used fMRI to investigate how brains recognize faces and retrieve associated names. They found that specific areas, including the medial prefrontal cortex, showed activation during 'feeling-of-knowing' states, suggesting additional processes aid in recalling accurate memories.
Researchers found that injecting antibodies directly into the brain of mice slowed down plaque growth by up to two months without adverse side effects. This modified passive immunization method may offer a safer treatment option for Alzheimer's, providing a window for other treatments to prevent new plaque formation.
New research from Newcastle University found that green and black tea inhibit the activity of certain enzymes in the brain linked to memory decline. The study suggests that drinking regular cups of tea may help improve memory and slow the development of Alzheimer's disease.
A recent study by University of Wisconsin-Madison scientists has identified a brain protein called transthyretin that appears to protect brain cells from toxic beta-amyloid, which contributes to Alzheimer's disease. The findings suggest that boosting transthyretin levels in the brain could be a promising approach to treating the disease.
Researchers found that stem cells in mice with Alzheimer's disease were attracted to abnormal protein bundles called amyloid plaques. This could lead to the development of plaque-busting treatments using adult olfactory bulb stem cells.
Researchers found an enzymatic pathway called Rho/ROCK plays a key role in the metabolism of APP, which is associated with Alzheimer's. The discovery may lead to novel anti-amyloid drugs and more specific therapies for Alzheimer's patients.